OraSure Technologies Stock News

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2021 Results - Earnings Call Transcript

OraSure Technologies press release (NASDAQ:OSUR): Q4 GAAP EPS of -$0.14 beats by $0.02.Revenue of $63.57M (+1.1% Y/Y) beats by $3.58M.

Total 2021 revenue of $233.7 million, up 36% year-over year

OraSure Technologies (NASDAQ:OSUR) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is -$0.18

BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2022.

BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certai

OraSure Technologies has filed for a $300M mixed shelf offering.

The risk of developing severe COVID-19 for people who are fully vaccinated and have received a booster dose is close to zero, according to the latest data from the Centers for Disease Control and Prev

Data Demonstrates InteliSwab® is Accurate, Easy to Use, and Well Accepted by Children

Data Demonstrates InteliSwab ® is Accurate, Easy to Use, and Well Accepted by Children BETHLEHEM, Pa., Jan. 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab ® COVID-19 rapid tests have been authorized by the U.S. Food and Drug Administration (FDA) for use in children ages 2 to 14. InteliSwab ® was previously authorized for use in adults and in children 15 to 17 when administered by an adult. As part of its submission to the FDA for this label expansion, the Company conducted studies to evaluate the performance of the test in a pediatric population, as well as studies to evaluate usability and tolerability by children. From a combined performance perspective, InteliSwab ® was shown to have 85 percent positive percent agreement (PPA) for individuals ages 2 and up and 98 percent negative percent agreement (NPA). The overall accuracy of the InteliSwab ® test including a pediatric population is 93 percent, demonstrating similar accuracy when compared to the Company''s clinical studies in adults.

Shares of OraSure Technologies Inc. OSUR, +5.09% gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2

BETHLEHEM, Pa., Jan. 25, 2022 (GLOBE NEWSWIRE) --  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announ

BETHLEHEM, Pa., Jan. 13, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announce

Orasure Technologies Inc. (OSUR) shares closed 1.1% lower than its previous 52 week low, giving the company a market cap of $590M. The stock is currently down 5.6% year-to-date, down 26.9% over the past 12 months, and down 8.3% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 0.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 67.6% The company's stock price performance over the past 12 months lags the peer average by 60.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.